These CCR3 antagonists have been carefully designed and tested to target kallikrein-related peptidase 7 (KLK7), a specific enzyme that plays a crucial role in skin homeostasis. KLK7 has been linked to various skin disorders, including dermatitis, psoriasis, and the Netherton syndrome. m2cobalt's products are the result of extensive molecular dynamics simulation research and structure-based design efforts.

These products offer a promising approach for the development of drug-like inhibitors that can effectively target the kallikrein family. With a focus on advancing the rational design of inhibitors, m2cobalt provides high-quality and reliable solutions for researchers and pharmaceutical companies looking to develop innovative therapies for skin diseases and cancer. Their expertise in molecular dynamics simulations and extensive knowledge of the KLK7 enzyme make them a trusted partner in drug discovery and development